Publications by authors named "Jifeng Feng"
Article Synopsis
- A phase 3 study showed that combining camrelizumab with chemotherapy significantly improved progression-free survival in patients with advanced non-squamous non-small-cell lung cancer compared to chemotherapy alone.
- After 5 years, overall survival rates were 31.2% for those receiving camrelizumab and chemotherapy versus 19.3% for those on chemotherapy alone, indicating a substantial benefit.
- Patients who completed two years of treatment with camrelizumab had an impressive 5-year overall survival rate of 84.3%, reinforcing its effectiveness and safety as a first-line therapy for this cancer type.
Pinocembrin alleviates LPS-induced depressive-like behavior in mice via the NLRP3/DCC signaling pathway.
Biochem Biophys Res Commun
December 2024
Article Synopsis
- The study investigates the connection between inflammation and depression, proposing Pinocembrin (PB), a natural compound with anti-inflammatory properties, as a potential treatment for depression in mouse models.
- Using an inflammation-inducing agent, lipopolysaccharide (LPS), the researchers assessed the effects of PB and an inflammasome inhibitor on behavior associated with depression.
- Results indicated that both PB and the inhibitor improved depressive behaviors in mice by reducing neuroinflammation and modulating specific cellular pathways related to depression.
Article Synopsis
- Abemaciclib, the first CDK4/6 inhibitor approved for high-risk hormone-receptor positive early breast cancer, showed positive results based on the phase III monarchE trial, particularly in a Chinese population analysis.
- In this study, 501 Chinese patients with high-risk early breast cancer were randomized to receive either abemaciclib plus endocrine therapy or endocrine therapy alone, with the primary focus on invasive disease-free survival and other key endpoints.
- The findings indicated that the combination of abemaciclib with endocrine therapy significantly improved invasive disease-free survival and distant relapse-free survival rates at the 5-year mark, though it was associated with a higher incidence of certain side effects like neutropenia and leukopenia.
Article Synopsis
- Zorifertinib is an experimental cancer drug that targets mutations in the EGFR gene and has shown effectiveness in patients with lung cancer that has spread to the brain.
- A phase 3 trial compared zorifertinib to standard treatments and found that it significantly extended the time patients lived without the disease worsening (progression-free survival).
- Results indicate that zorifertinib may be a better first-line treatment option for non-small cell lung cancer due to its ability to improve survival and manage side effects effectively.
Article Synopsis
- There is a need for better second- and third-line treatments for advanced non-small-cell lung cancer (NSCLC) without driver mutations, prompting a clinical trial.
- The trial involved 559 eligible patients with NSCLC who had failed first-line treatment and tested the effectiveness of docetaxel combined with either plinabulin or a placebo.
- Results showed that the plinabulin group had a longer median overall survival (10.5 months) compared to the placebo group (9.4 months), with over 99% of patients experiencing treatment-related adverse events.
FN-1501 Inhibits Diffuse Large B-Cell Lymphoma Tumor Growth by Inducing Cell Cycle Arrest and Apoptosis.
Anticancer Agents Med Chem
October 2024
Background: Due to its high degree of aggressiveness, diffuse large B-cell lymphoma (DLBCL) presents a treatment challenge because 30% to 50% of patients experience resistance or relapse following standard chemotherapy. FN-1501 is an effective inhibitor of cyclin-dependent kinases and Fms-like receptor tyrosine kinase 3.
Objective: This study aimed to examine the anti-tumor impact of FN-1501 on DLBCL and clarify its molecular mechanism.
The obstacle to effectively treating Diffuse Large B-cell Lymphoma (DLBCL) lies in the resistance observed toward standard therapies. Identifying therapeutic targets that prove effective for relapsed or refractory patients poses a significant challenge. OTUD3, a deubiquitinase enzyme, is overexpressed in DLBCL tissues.
View Article and Find Full Text PDFCopanlisib, a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α and δ isoforms, previously demonstrated durable responses as monotherapy and improved progression-free survival (PFS) in combination with rituximab in patients with relapsed indolent non-Hodgkin lymphoma (iNHL). CHRONOS-4 was a phase 3, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of copanlisib in combination with standard immunochemotherapy in patients with relapsed iNHL. Patients (n = 524) were randomized (1:1) to copanlisib (60 mg IV) plus immunochemotherapy (rituximab and bendamustine [R-B] or placebo plus R-B).
View Article and Find Full Text PDFBackground: To investigate the relationship between the Scottish inflammatory prognostic score (SIPS), treatment-related adverse events (TRAEs), and prognostication in patients with neoadjuvant immunochemotherapy (NICT) for esophageal squamous cell carcinoma (ESCC).
Methods: A retrospective investigation was carried out on 208 ESCC patients treated with NICT. The relationships between the SIPS, TRAEs, and prognosis [disease-free survival (DFS) and overall survival (OS)] were analyzed.
Article Synopsis
- A study called ANEAS compared two cancer treatments, aumolertinib and gefitinib, for patients with advanced lung cancer that had spread to the brain.
- The results showed that aumolertinib worked much better, helping patients live longer without their brain cancer getting worse compared to gefitinib.
- Overall, more patients treated with aumolertinib responded well to the treatment, showing an improvement in their condition compared to those who received gefitinib.
The role of the aryl hydrocarbon receptor (AhR) in regulating oxidative stress and immune responses has been increasingly recognized. However, its involvement in depression and the underlying mechanisms remain poorly understood. This study aimed to investigate the effect of 6-formylindolo[3,2-b]carbazole (FICZ), an endogenous AhR ligand, on a lipopolysaccharide (LPS)-induced depression model and the underlying mechanism.
View Article and Find Full Text PDFBackground & Aims: Portal hypertension (PH) is one of the most frequent complications of chronic liver disease. The peripheral 5-hydroxytryptamine (5-HT) level was increased in cirrhotic patients. We aimed to elucidate the function and mechanism of 5-HT receptor 1A (HTR1A) in the portal vein (PV) on PH.
View Article and Find Full Text PDFBackground: The global BOLERO-2 trial established the efficacy and safety of combination everolimus (EVE) and exemestane (EXE) in the treatment of estrogen receptor positive (ER +), HER2-, advanced breast cancer (ABC). BOLERO-5 investigated this combination in a Chinese population (NCT03312738).
Methods: BOLERO-5 is a randomized, double-blind, multicenter, placebo controlled, phase II trial comparing EVE (10 mg/day) or placebo (PBO) in combination with EXE (25 mg/day).
Background: The interim analysis of the randomized phase 3 ESCORT-1st study demonstrated significantly longer overall survival (OS) and progression-free survival (PFS) for camrelizumab-chemotherapy than placebo-chemotherapy in untreated advanced/metastatic esophageal squamous cell carcinoma (ESCC). Here, we present the final analysis of this study and investigate potential indicators associated with OS.
Methods: Patients were randomized 1:1 to receive camrelizumab (200 mg) or placebo, both in combination with up to six cycles of paclitaxel (175 mg/m) and cisplatin (75 mg/m).
Article Synopsis
- Patients with non-small cell lung cancer who experienced disease progression on EGFR tyrosine kinase inhibitors (TKIs), especially third-generation ones, have limited treatment options available.* -
- The study aimed to compare the effectiveness of ivonescimab in conjunction with chemotherapy versus chemotherapy alone for patients with relapsed advanced or metastatic non-small cell lung cancer with EGFR variants.* -
- Results showed that the median progression-free survival was significantly higher in the ivonescimab group (7.1 months) compared to the placebo group (4.8 months), indicating a promising benefit for those receiving ivonescimab.*
Objective: IMpower210 (NCT02813785) explored the efficacy and safety of single-agent atezolizumab docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC) in East Asian patients.
Methods: Key eligibility criteria for this phase III, open-label, randomized study included age ≥18 years; histologically documented advanced NSCLC per the Union for International Cancer Control/American Joint Committee on Cancer staging system (7th edition); Eastern Cooperative Oncology Group performance status of 0 or 1; and disease progression following platinum-based chemotherapy for advanced or metastatic NSCLC. Patients were randomized 2:1 to receive either atezolizumab (1,200 mg) or docetaxel (75 mg/m).
Background: The combination of immune checkpoint inhibitors and antiangiogenic agents has been effective in treating multiple cancers. This was further explored in an open-label, multicenter phase 2 basket study (NCT04346381), which evaluated the antitumor activity and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (a receptor tyrosine kinase inhibitor) in patients with advanced solid tumors. We herein report the findings from the cohort of advanced NSCLC patients who progressed after treatment with platinum-doublet chemotherapy and immunotherapy.
View Article and Find Full Text PDFPhase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma.
Signal Transduct Target Ther
April 2024
This registration study assessed clinical outcomes of TQ-B3525, the dual phosphatidylinositol-3-kinase (PI3K) α/δ inhibitor, in relapsed and/or refractory follicular lymphoma (R/R FL). This phase II study (ClinicalTrials.gov NCT04324879.
View Article and Find Full Text PDFBackground: Immune checkpoint inhibitors (ICIs) have dramatically changed the first-line treatment pattern of non-small cell lung cancer (NSCLC) without driver gene alterations. However, the optimal choice for second-line treatment after initial treatment with ICIs is unclear. This study aimed to clarify the efficacy and safety of ICI rechallenge therapy in locally advanced and advanced NSCLC.
View Article and Find Full Text PDFArticle Synopsis
- Metastatic triple-negative breast cancer (mTNBC) has the poorest prognosis among breast cancer types, but combining immune checkpoint inhibitors (ICIs) with chemotherapy shows promise for improving survival.
- The case study highlights a 51-year-old woman with mTNBC who had significant success using the combination treatment of tislelizumab (an ICI) and eribulin (a chemotherapy drug).
- This research is unique in exploring the effectiveness of tislelizumab and eribulin together for mTNBC, and it discusses factors that may influence how these two treatments work together.
Objective: The geriatric nutritional risk index (GNRI) is a novel nutrition-related indicator designed to predict the risk of clinical outcomes in various cancers. The clinical significance of risk assessment, therapeutic response, and prognostic prediction of GNRI in esophageal squamous cell carcinoma (ESCC) receiving neoadjuvant immunochemotherapy (NICT), a hot point of treatment these days, have not been documented in any research.
Methods: Two hundred and twenty-four cases with ESCC who underwent radical resection after NICT were retrospectively recruited.